Risk of Progression to Kidney Failure in IgA Nephropathy
This infographic highlights the risk of progression to ESKD, including in patients traditionally considered low risk. Read More
- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
IgAN
APRIL & the 4-Hit Pathogenic Cascade of IgAN
This infographic highlights the role of APRIL in a pre-hit 1 step that drives the 4-hit cascade.1 References 1. Mathur M, et al. J Clin Med. 2023;12(21):6927. Read More4 Part IgAN Experience
During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. Read MoreKey Messages from KDIGO IgAN Experts (2025)
These videos are part of a three-part series featuring IgA Nephropathy (IgAN) experts and Work Group Members of the forthcoming KDIGO 2025 IgAN Guideline Update sharing key insights on emerging… Read MoreIgA Nephropathy: Early Signs & Symptoms, Disease Burden, & Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read MoreNavigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy
This webinar will focus on the current biomarker landscape as well as novel biomarkers that are currently being studied. The webinar will also focus on why biomarkers are needed and… Read MoreIgA Nephropathy: Pathogenesis, the Role of APRIL & the 4-Hit Process, & a Patient Case Study
The goal of this event is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis. Read MoreIgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read MoreA Targeted Approach for Immunoglobulin-A Nephropathy
Dr. Srinivasan will discuss the four hit pathogenic process of IgA nephropathy, including the role of galactose deficient immunoglobulin-A1 (Gd-IgA1) and A-proliferation inducing ligand (APRIL). Read More4 Part IgAN Experience
An innovative, four-part educational experience designed to immerse healthcare professionals in the evolving landscape of IgA Nephropathy (IgAN) through interactive technology, evidence-based literature, real-world case studies, and high-impact educational tools. Read MoreNephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
